Definitive Healthcare’s share price is down roughly 36–40% over the past 6–12 months and trades near the lower end of its 52-week range, although recent technical signals point to short-term momentum stabilizing with multiple bullish indicator crossovers. Fundamentally, the company combines high gross margins and positive free cash flow with large GAAP operating and net losses and slightly negative revenue growth. Short interest metrics show elevated days-to-cover and a high short-volume ratio, while the news backdrop has recently been dominated by investigations following a substantial goodwill impairment and guidance reduction.